Effects	O
of	O
Obesity	B:C0028754
and	O
Leptin	O
Deficiency	I:C3554224
on	O
Morphine	O
Pharmacokinetics	O
in	O
a	O
Mouse	O
Model	I:C2986594
.	O

Effects	O
of	O
Obesity	O
and	O
Leptin	B:C3554224
Deficiency	I:C3554224
on	O
Morphine	O
Pharmacokinetics	O
in	O
a	O
Mouse	O
Model	I:C2986594
.	O

Effects	O
of	O
Obesity	O
and	O
Leptin	O
Deficiency	I:C3554224
on	O
Morphine	B:C0026549
Pharmacokinetics	O
in	O
a	O
Mouse	O
Model	I:C2986594
.	O

Effects	O
of	O
Obesity	O
and	O
Leptin	O
Deficiency	I:C3554224
on	O
Morphine	O
Pharmacokinetics	B:C0031327
in	O
a	O
Mouse	O
Model	I:C2986594
.	O

Effects	O
of	O
Obesity	O
and	O
Leptin	O
Deficiency	I:C3554224
on	O
Morphine	O
Pharmacokinetics	O
in	O
a	O
Mouse	B:C2986594
Model	I:C2986594
.	O

Obesity	B:C0028754
causes	O
multiorgan	O
dysfunction	I:C0026766
,	O
specifically	O
metabolic	O
abnormalities	I:C1704258
in	O
the	O
liver	O
.	O

Obesity	O
causes	O
multiorgan	B:C0026766
dysfunction	I:C0026766
,	O
specifically	O
metabolic	O
abnormalities	I:C1704258
in	O
the	O
liver	O
.	O

Obesity	O
causes	O
multiorgan	O
dysfunction	I:C0026766
,	O
specifically	O
metabolic	B:C1704258
abnormalities	I:C1704258
in	O
the	O
liver	O
.	O

Obesity	O
causes	O
multiorgan	O
dysfunction	I:C0026766
,	O
specifically	O
metabolic	O
abnormalities	I:C1704258
in	O
the	O
liver	B:C0023884
.	O

Obese	B:C0028754
patients	O
are	O
opioid	O
-	O
sensitive	O
and	O
have	O
high	O
rates	O
of	O
respiratory	O
complications	I:C0161818
after	O
surgery	O
.	O

Obese	O
patients	O
are	O
opioid	B:C0242402
-	O
sensitive	O
and	O
have	O
high	O
rates	O
of	O
respiratory	O
complications	I:C0161818
after	O
surgery	O
.	O

Obese	O
patients	O
are	O
opioid	O
-	O
sensitive	O
and	O
have	O
high	O
rates	O
of	O
respiratory	B:C0161818
complications	I:C0161818
after	O
surgery	O
.	O

Obese	O
patients	O
are	O
opioid	O
-	O
sensitive	O
and	O
have	O
high	O
rates	O
of	O
respiratory	O
complications	I:C0161818
after	O
surgery	B:C0543467
.	O

Obesity	B:C0028754
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	B:C0299583
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	B:C0001527
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	B:C0019932
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	B:C1327622
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	B:C0020175
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	B:C0025519
,	O
and	O
respiratory	O
stimulation	O
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-	O
derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	B:C0038337
.	O

We	O
hypothesized	O
that	O
obesity	B:C0028754
and	O
leptin	O
deficiency	I:C3554224
impair	O
opioid	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
independently	O
of	O
one	O
another	O
.	O

We	O
hypothesized	O
that	O
obesity	O
and	O
leptin	B:C3554224
deficiency	I:C3554224
impair	O
opioid	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
independently	O
of	O
one	O
another	O
.	O

We	O
hypothesized	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
impair	O
opioid	B:C0242402
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
independently	O
of	O
one	O
another	O
.	O

We	O
hypothesized	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
impair	O
opioid	O
pharmacokinetics	B:C0031327
(	O
pharmacokinetics	O
)	O
independently	O
of	O
one	O
another	O
.	O

We	O
hypothesized	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
impair	O
opioid	O
pharmacokinetics	O
(	O
pharmacokinetics	B:C0031327
)	O
independently	O
of	O
one	O
another	O
.	O

Morphine	B:C0026549
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	B:C0031327
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	B:C1516103
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	B:C1520150
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	B:C1520150
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	B:C0025933
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	B:C0025933
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	B:C0025933
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	O
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

Morphine	O
pharmacokinetics	O
were	O
characterized	O
in	O
C57BL	O
/	I:C1516103
6J	I:C1516103
wild	O
-	I:C1520150
type	I:C1520150
(	O
wild	O
-	I:C1520150
type	I:C1520150
)	O
,	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	I:C0025933
DIO	I:C0025933
)	I:C0025933
,	O
and	O
leptin	O
-	I:C0025933
deficient	I:C0025933
(	I:C0025933
ob	I:C0025933
/	I:C0025933
ob	I:C0025933
)	I:C0025933
mice	I:C0025933
,	O
and	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
given	O
leptin	B:C0282402
-	I:C0282402
replacement	I:C0282402
(	I:C0282402
LR	I:C0282402
)	I:C0282402
therapy	I:C0282402
.	O

WT	B:C1520150
mice	I:C1520150
received	O
several	O
dosing	O
regimens	O
of	O
morphine	O
.	O

WT	O
mice	I:C1520150
received	O
several	O
dosing	O
regimens	B:C2945654
of	O
morphine	O
.	O

WT	O
mice	I:C1520150
received	O
several	O
dosing	O
regimens	O
of	O
morphine	B:C0026549
.	O

Obese	B:C0025933
mice	I:C0025933
(	O
30	O
g	O
)	O
received	O
one	O
80	O
mg	O
/	O
kg	O
bolus	O
of	I:C0026549
morphine	I:C0026549
.	O

Obese	O
mice	I:C0025933
(	O
30	O
g	O
)	O
received	O
one	O
80	O
mg	O
/	O
kg	O
bolus	B:C0026549
of	I:C0026549
morphine	I:C0026549
.	O

Blood	B:C0005767
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	O
for	O
quantification	O
of	O
plasma	O
morphine	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	B:C0026549
injection	O
for	O
quantification	O
of	O
plasma	O
morphine	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	B:C0021485
for	O
quantification	O
of	O
plasma	O
morphine	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	O
for	O
quantification	O
of	O
plasma	B:C0032105
morphine	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	O
for	O
quantification	O
of	O
plasma	O
morphine	B:C0026549
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	O
for	O
quantification	O
of	O
plasma	O
morphine	O
and	O
morphine	B:C0066815
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
(	I:C0066815
M3G	I:C0066815
)	I:C0066815
levels	O
.	O

pharmacokinetics	B:C0031327
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	B:C0449381
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	B:C0220825
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	B:C0026549
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	B:C0025519
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	B:C0026549
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	B:C0066815
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	B:C0026549
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	B:C1382187
(	O
Cl	O
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area	O
-	O
under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl	B:C1382187
/	I:C1382187
F	I:C1382187
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half	O
-	O
life	O
(	O
T1/2	O
)	O
.	O

pharmacokinetics	B:C0031327
parameters	O
were	O
compared	O
between	O
mouse	O
groups	O
by	O
the	O
use	O
of	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
with	O
P	O
values	O
less	O
than	O
.05	O
considered	O
significant	O
.	O

pharmacokinetics	O
parameters	B:C0449381
were	O
compared	O
between	O
mouse	O
groups	O
by	O
the	O
use	O
of	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
with	O
P	O
values	O
less	O
than	O
.05	O
considered	O
significant	O
.	O

pharmacokinetics	O
parameters	O
were	O
compared	O
between	O
mouse	B:C0025929
groups	O
by	O
the	O
use	O
of	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
with	O
P	O
values	O
less	O
than	O
.05	O
considered	O
significant	O
.	O

diet	B:C0025933
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	B:C1520150
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	B:C0026549
metabolism	O
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	B:C0025519
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
morphine	B:C0066815
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	B:C0026549
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-	O
4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-	O
8.8	O
to	O
-	O
0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl	B:C1382187
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
4.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
8.9	O
to	O
-	O
0.03	O
)	O

Ob	B:C0025933
/	I:C0025933
ob	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
a	O
large	O
increase	O
in	O
morphine	O
exposure	O
with	O
a	O
greater	O
AUC150	O
(	O
MD	O
:	O
980.4	O
;	O
95	O
%	O
CI	O
:	O
630.1-1330.6	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
6.8	O
;	O
95	O
%	O
CI	O
:	O
2.7-10.9	O
)	O
,	O
and	O
longer	O
T1/2	O
(	O
MD	O
:	O
23.1	O
;	O
95	O
%	O
CI	O
:	O
10.5	O
-	O
35.6	O
)	O
,	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
7.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.6	O
to	O
-	O
2.7	O
)	O
.	O

Ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
WT	B:C1520150
mice	I:C1520150
had	O
a	O
large	O
increase	O
in	O
morphine	O
exposure	O
with	O
a	O
greater	O
AUC150	O
(	O
MD	O
:	O
980.4	O
;	O
95	O
%	O
CI	O
:	O
630.1-1330.6	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
6.8	O
;	O
95	O
%	O
CI	O
:	O
2.7-10.9	O
)	O
,	O
and	O
longer	O
T1/2	O
(	O
MD	O
:	O
23.1	O
;	O
95	O
%	O
CI	O
:	O
10.5	O
-	O
35.6	O
)	O
,	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
7.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.6	O
to	O
-	O
2.7	O
)	O
.	O

Ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
a	O
large	O
increase	O
in	O
morphine	B:C0026549
exposure	O
with	O
a	O
greater	O
AUC150	O
(	O
MD	O
:	O
980.4	O
;	O
95	O
%	O
CI	O
:	O
630.1-1330.6	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
6.8	O
;	O
95	O
%	O
CI	O
:	O
2.7-10.9	O
)	O
,	O
and	O
longer	O
T1/2	O
(	O
MD	O
:	O
23.1	O
;	O
95	O
%	O
CI	O
:	O
10.5	O
-	O
35.6	O
)	O
,	O
as	O
well	O
as	O
a	O
decreased	O
Cl	O
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
7.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.6	O
to	O
-	O
2.7	O
)	O
.	O

Ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
WT	O
mice	I:C1520150
had	O
a	O
large	O
increase	O
in	O
morphine	O
exposure	O
with	O
a	O
greater	O
AUC150	O
(	O
MD	O
:	O
980.4	O
;	O
95	O
%	O
CI	O
:	O
630.1-1330.6	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
6.8	O
;	O
95	O
%	O
CI	O
:	O
2.7-10.9	O
)	O
,	O
and	O
longer	O
T1/2	O
(	O
MD	O
:	O
23.1	O
;	O
95	O
%	O
CI	O
:	O
10.5	O
-	O
35.6	O
)	O
,	O
as	O
well	O
as	O
a	O
decreased	O
Cl	B:C1382187
/	I:C1382187
F	I:C1382187
(	O
MD	O
:	O
-	O
7.0	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.6	O
to	O
-	O
2.7	O
)	O
.	O

Several	O
pharmacokinetics	B:C0031327
parameters	O
were	O
significantly	O
greater	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
DIO	O
mice	I:C0025933
,	O
including	O
AUC150	O
(	O
MD	O
:	O
636.4	O
;	O
95	O
%	O
CI	O
:	O
207.4-1065.4	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
3.2-10.3	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
18.3	O
;	O
95	O
%	O
CI	O
:	O
2.8-33.7	O
)	O
.	O

Several	O
pharmacokinetics	O
parameters	B:C0449381
were	O
significantly	O
greater	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
DIO	O
mice	I:C0025933
,	O
including	O
AUC150	O
(	O
MD	O
:	O
636.4	O
;	O
95	O
%	O
CI	O
:	O
207.4-1065.4	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
3.2-10.3	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
18.3	O
;	O
95	O
%	O
CI	O
:	O
2.8-33.7	O
)	O
.	O

Several	O
pharmacokinetics	O
parameters	O
were	O
significantly	O
greater	O
in	O
ob	B:C0025933
/	I:C0025933
ob	I:C0025933
compared	O
with	O
DIO	O
mice	I:C0025933
,	O
including	O
AUC150	O
(	O
MD	O
:	O
636.4	O
;	O
95	O
%	O
CI	O
:	O
207.4-1065.4	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
3.2-10.3	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
18.3	O
;	O
95	O
%	O
CI	O
:	O
2.8-33.7	O
)	O
.	O

Several	O
pharmacokinetics	O
parameters	O
were	O
significantly	O
greater	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
compared	O
with	O
DIO	B:C0025933
mice	I:C0025933
,	O
including	O
AUC150	O
(	O
MD	O
:	O
636.4	O
;	O
95	O
%	O
CI	O
:	O
207.4-1065.4	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
3.2-10.3	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
18.3	O
;	O
95	O
%	O
CI	O
:	O
2.8-33.7	O
)	O
.	O

When	O
leptin	B:C0299583
was	O
replaced	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	O
parameters	O
began	O
to	O
approach	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	O
-	I:C1520150
type	I:C1520150
levels	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob	B:C0025933
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	O
parameters	O
began	O
to	O
approach	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	O
-	I:C1520150
type	I:C1520150
levels	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	B:C0031327
parameters	O
began	O
to	O
approach	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	O
-	I:C1520150
type	I:C1520150
levels	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	O
parameters	B:C0449381
began	O
to	O
approach	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	O
-	I:C1520150
type	I:C1520150
levels	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	O
parameters	O
began	O
to	O
approach	O
diet	B:C0025933
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	O
-	I:C1520150
type	I:C1520150
levels	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	I:C0025933
,	O
pharmacokinetics	O
parameters	O
began	O
to	O
approach	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
and	O
wild	B:C1520150
-	I:C1520150
type	I:C1520150
levels	O
.	O

leptin	B:C0282402
-	I:C0282402
replacement	I:C0282402
compared	O
with	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	O
had	O
significant	O
decreases	O
in	O
AUC150	O
(	O
MD	O
:	O
-	O
779.9	O
;	O
95	O
%	O
CI	O
:	O
-	O
1229.8	O
to	O
-	O
330	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
-	O
6.1	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.4	O
to	O
-	O
0.9	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
-	O
19	O
;	O
95	O
%	O
CI	O
:	O
-	O
35.1	O
to	O
-	O
2.8	O
)	O
.	O

leptin	O
-	I:C0282402
replacement	I:C0282402
compared	O
with	O
ob	B:C0025933
/	I:C0025933
ob	I:C0025933
mice	O
had	O
significant	O
decreases	O
in	O
AUC150	O
(	O
MD	O
:	O
-	O
779.9	O
;	O
95	O
%	O
CI	O
:	O
-	O
1229.8	O
to	O
-	O
330	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
-	O
6.1	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.4	O
to	O
-	O
0.9	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
-	O
19	O
;	O
95	O
%	O
CI	O
:	O
-	O
35.1	O
to	O
-	O
2.8	O
)	O
.	O

leptin	O
-	I:C0282402
replacement	I:C0282402
compared	O
with	O
ob	O
/	I:C0025933
ob	I:C0025933
mice	B:C0025933
had	O
significant	O
decreases	O
in	O
AUC150	O
(	O
MD	O
:	O
-	O
779.9	O
;	O
95	O
%	O
CI	O
:	O
-	O
1229.8	O
to	O
-	O
330	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
-	O
6.1	O
;	O
95	O
%	O
CI	O
:	O
-	O
11.4	O
to	O
-	O
0.9	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
-	O
19	O
;	O
95	O
%	O
CI	O
:	O
-	O
35.1	O
to	O
-	O
2.8	O
)	O
.	O

Metabolism	B:C0025519
increased	O
with	O
leptin-	O
replacement	I:C0282402
,	O
with	O
LR	O
mice	I:C0025929
having	O
a	O
greater	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
compared	O
with	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Metabolism	O
increased	O
with	O
leptin-	B:C0282402
replacement	I:C0282402
,	O
with	O
LR	O
mice	I:C0025929
having	O
a	O
greater	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
compared	O
with	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Metabolism	O
increased	O
with	O
leptin-	O
replacement	I:C0282402
,	O
with	O
LR	B:C0025929
mice	I:C0025929
having	O
a	O
greater	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
compared	O
with	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Metabolism	O
increased	O
with	O
leptin-	O
replacement	I:C0282402
,	O
with	O
LR	O
mice	I:C0025929
having	O
a	O
greater	O
morphine	B:C0066815
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
compared	O
with	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Metabolism	O
increased	O
with	O
leptin-	O
replacement	I:C0282402
,	O
with	O
LR	O
mice	I:C0025929
having	O
a	O
greater	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	B:C0026549
ratio	O
compared	O
with	O
diet	O
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Metabolism	O
increased	O
with	O
leptin-	O
replacement	I:C0282402
,	O
with	O
LR	O
mice	I:C0025929
having	O
a	O
greater	O
morphine	O
3	I:C0066815
-	I:C0066815
glucuronide	I:C0066815
-	O
to	O
-	O
morphine	O
ratio	O
compared	O
with	O
diet	B:C0025933
-	I:C0025933
induced	I:C0025933
obese	I:C0025933
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Systemic	O
effects	O
associated	O
with	O
obesity	B:C0028754
decrease	O
morphine	O
metabolism	O
and	O
excretion	O
.	O

Systemic	O
effects	O
associated	O
with	O
obesity	O
decrease	O
morphine	B:C0026549
metabolism	O
and	O
excretion	O
.	O

Systemic	O
effects	O
associated	O
with	O
obesity	O
decrease	O
morphine	O
metabolism	B:C0025519
and	O
excretion	O
.	O

Systemic	O
effects	O
associated	O
with	O
obesity	O
decrease	O
morphine	O
metabolism	O
and	O
excretion	B:C0221102
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	B:C0022877
demonstrated	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
decrease	O
the	O
sensitivity	O
of	O
central	O
respiratory	I:C0460002
control	I:C0460002
centers	I:C0460002
to	O
carbon	O
dioxide	I:C0007012
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
obesity	B:C0028754
and	O
leptin	O
deficiency	I:C3554224
decrease	O
the	O
sensitivity	O
of	O
central	O
respiratory	I:C0460002
control	I:C0460002
centers	I:C0460002
to	O
carbon	O
dioxide	I:C0007012
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
obesity	O
and	O
leptin	B:C3554224
deficiency	I:C3554224
decrease	O
the	O
sensitivity	O
of	O
central	O
respiratory	I:C0460002
control	I:C0460002
centers	I:C0460002
to	O
carbon	O
dioxide	I:C0007012
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
decrease	O
the	O
sensitivity	O
of	O
central	B:C0460002
respiratory	I:C0460002
control	I:C0460002
centers	I:C0460002
to	O
carbon	O
dioxide	I:C0007012
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
obesity	O
and	O
leptin	O
deficiency	I:C3554224
decrease	O
the	O
sensitivity	O
of	O
central	O
respiratory	I:C0460002
control	I:C0460002
centers	I:C0460002
to	O
carbon	B:C0007012
dioxide	I:C0007012
.	O

Obesity	B:C0028754
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	B:C3554224
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	B:C0026549
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	B:C0025519
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	B:C1382187
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	B:C0299583
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	B:C0031327
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	B:C3554224
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	B:C0299583
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	B:C0026549
metabolism	O
.	O

Obesity	O
and	O
leptin	O
deficiency	I:C3554224
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
pharmacokinetics	O
changes	O
associated	O
with	O
leptin	O
deficiency	I:C3554224
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	B:C0025519
.	O

